{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:19:29Z","timestamp":1787163569220,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Perioperative immunotherapy has emerged as an important strategy in the management of resectable gastric and gastroesophageal junction adenocarcinoma. Phase II and III studies combining immune checkpoint inhibitors with chemotherapy have shown higher pathological response rates and improvements in event-free outcomes, particularly in molecularly selected groups such as HER2-positive and MSI-H or dMMR tumors. MSI-H and dMMR cancers show marked sensitivity to immune treatment, often achieving high rates of pathological complete response. Combinations that include HER2-directed therapy and immunotherapy have also produced encouraging antitumor activity. However, the results in broader, unselected populations remain variable, and reliable predictive markers such as PD-L1 are still lacking. While safety profiles are generally acceptable, some treatment regimens, especially those involving antiangiogenic agents or dual checkpoint blockade, call for careful perioperative evaluation. Importantly, despite improvements in pathological and early clinical outcomes, the impact on overall survival has been limited so far, and longer follow-up is needed to clarify the true survival benefit. Future progress will depend on better patient selection through integrated molecular and immune markers, more thoughtful sequencing of therapies, and the development of combination strategies that can enhance the durability of response. These findings highlight both the promise of perioperative immunotherapy and the need for continued efforts to achieve meaningful survival gains.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1722749","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:20:53Z","timestamp":1765948853000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Perioperative immunotherapy in gastric cancer: walking a fine line between hope and caution"],"prefix":"10.3389","volume":"16","author":[{"given":"Xianlei","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congcong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"159580","DOI":"10.1016\/j.bbalip.2024.159580","article-title":"RBM15 promotes lipogenesis and Malignancy in gastric cancer by regulating N6-Methyladenosine modification of ACLY mRNA in an IGF2BP2-dependent manner","volume":"1870","author":"Cai","year":"2025","journal-title":"Biochim Et Biophys Acta-Molecular Cell Biol Lipids"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-031-61238-1_14","article-title":"Immunotherapy in gastrointestinal cancers","volume":"192","author":"Lote","year":"2024","journal-title":"Cancer Treat Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e078876","DOI":"10.1136\/bmj-2023-078876","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial","volume":"385","author":"Qiu","year":"2024","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00541-7","article-title":"Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study","volume":"25","author":"Shitara","year":"2024","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00795","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00156-0","article-title":"Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kang","year":"2024","journal-title":"Lancet Gastroenterol hepatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0369","article-title":"A phase II study of perioperative avelumab plus chemotherapy for patients with resectable gastric cancer or gastroesophageal junction cancer - the MONEO study","volume":"31","author":"Alsina","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001119","article-title":"Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study","volume":"110","author":"Li","year":"2024","journal-title":"Int J Surg (London England)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02721-w","article-title":"Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial","volume":"30","author":"Yuan","year":"2024","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41392-025-02160-8","article-title":"Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial","volume":"10","author":"Nie","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1038\/s41467-022-34403-5","article-title":"The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction","volume":"13","author":"Tang","year":"2022","journal-title":"Nat Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102190","DOI":"10.1016\/j.xcrm.2025.102190","article-title":"Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"6","author":"Nie","year":"2025","journal-title":"Cell Rep Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.0522","article-title":"Atezolizumab and trastuzumab plus chemotherapy for ERBB2-positive locally advanced resectable gastric cancer: A randomized clinical trial","volume":"11","author":"Peng","year":"2025","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01606-w","article-title":"Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial","volume":"28","author":"Ma","year":"2025","journal-title":"Gastric Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.016","article-title":"Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO","volume":"36","author":"Raimondi","year":"2025","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"103421","DOI":"10.1016\/j.eclinm.2025.103421","article-title":"Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study","volume":"87","author":"Zhao","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"102045","DOI":"10.1016\/j.xcrm.2025.102045","article-title":"Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: The role of M2 macrophage landscape in predicting response","volume":"6","author":"Alcindor","year":"2025","journal-title":"Cell Rep Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-24-2436","article-title":"Intestinal subtype as a biomarker of response to neoadjuvant immunochemotherapy in locally advanced gastric adenocarcinoma: insights from a prospective phase II trial","volume":"31","author":"Wang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16041-x","article-title":"Two-year outcomes and biomarker analysis of locally advanced gastric and gastroesophageal junction adenocarcinoma after neoadjuvant chemotherapy and immunotherapy from the phase II wuhanUHGI001 trial","volume":"31","author":"Sun","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"036115","DOI":"10.1063\/5.0250475","article-title":"PDPN+ cancer-associated fibroblasts correlate with the neoadjuvant immunotherapy response in gastric cancer","volume":"9","author":"Jian","year":"2025","journal-title":"APL bioengineering"},{"key":"B28","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s12885-025-14046-7","article-title":"Potential predictive value of CD8A and PGF protein expression in gastric cancer patients treated with neoadjuvant immunotherapy","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e010041","DOI":"10.1136\/jitc-2024-010041","article-title":"Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy","volume":"12","author":"Ji","year":"2024","journal-title":"J immunotherapy cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e7006","DOI":"10.1002\/cam4.7006","article-title":"Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study","volume":"13","author":"Zhong","year":"2024","journal-title":"Cancer Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002056","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor plus chemotherapy for patients with locally advanced gastric cancer: a systematic review and meta-analysis","volume":"111","author":"Yu","year":"2025","journal-title":"Int J Surg (London England)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1501415","article-title":"Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis\/cystitis treated by ureteral stent and review of the literature","volume":"15","author":"Ji","year":"2024","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","article-title":"Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and\/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"189350","DOI":"10.1016\/j.bbcan.2025.189350","article-title":"Tumor immune microenvironment remodeling after neoadjuvant therapy in gastric cancer: Update and new challenges","volume":"1880","author":"Sun","year":"2025","journal-title":"Biochim Biophys Acta Rev cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722749\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T05:20:54Z","timestamp":1765948854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1722749\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2025.1722749"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1722749","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1722749"}}